Medical Pharmacology: Chapter 37 — Antifungal Agents -- Module 5 — Antifungal Drug Interactions and Therapeutic Drug Monitoring

Chapter 37 — Antifungal Agents — Module 5 — Antifungal Drug Interactions and Therapeutic Drug Monitoring

1. A lung transplant recipient receiving tacrolimus and rifampin-based therapy for latent tuberculosis reactivation develops invasive aspergillosis. The team determines that voriconazole is required and that neither rifampin nor tacrolimus can be discontinued. A clinical pharmacist identifies two simultaneous drug interactions that will act in opposite directions on different drugs in this regimen. Which of the following correctly identifies both interactions and their clinical implications?

A) Rifampin will raise voriconazole concentrations through CYP inhibition, while voriconazole will lower tacrolimus concentrations through CYP induction — the net effect is unpredictable and no empiric dose adjustments should be made until TDM results return
B) Voriconazole will raise rifampin concentrations through CYP3A4 inhibition, creating rifampin toxicity risk; tacrolimus concentrations will be unaffected because rifampin and tacrolimus cancel each other's CYP effects
C) Rifampin has no effect on voriconazole because the lung is the primary site of voriconazole metabolism; voriconazole will raise tacrolimus concentrations, requiring tacrolimus dose reduction
D) Rifampin will reduce voriconazole concentrations by approximately 90% through potent CYP2C19 and CYP2C9 induction — requiring voriconazole dose doubling and mandatory TDM to confirm therapeutic exposure; simultaneously, voriconazole will inhibit CYP3A4 and raise tacrolimus concentrations by approximately 3- to 5-fold — requiring proactive tacrolimus dose reduction to approximately one-third and daily trough monitoring; both interactions must be managed concurrently and independently
E) The two interactions cancel each other out: rifampin-induced CYP upregulation counteracts voriconazole's CYP inhibitory effect on tacrolimus, so tacrolimus concentrations remain stable and no dose adjustment is required

ANSWER: D

Rationale:

Option D is correct. This scenario illustrates one of the most pharmacokinetically complex situations in antifungal prescribing — the simultaneous management of two independent, directionally distinct drug interactions within the same regimen. The first interaction: rifampin is a potent inducer of CYP2C19 and CYP2C9, the primary enzymes responsible for voriconazole metabolism, reducing voriconazole plasma concentrations by approximately 90% at standard doses. To achieve any chance of therapeutic voriconazole exposure, the maintenance dose must be doubled to 400 mg oral twice daily and TDM obtained to confirm troughs are within the 1.0 to 5.5 mg/L therapeutic window; even at doubled doses, TDM may reveal subtherapeutic concentrations requiring further escalation or antifungal strategy change. The second interaction: voriconazole is a potent CYP3A4 inhibitor, and tacrolimus is metabolized almost entirely by CYP3A4. Co-administration raises tacrolimus area under the concentration-time curve by approximately 3- to 5-fold; to prevent calcineurin inhibitor toxicity, tacrolimus must be empirically reduced to approximately one-third of its current dose before the first voriconazole dose, with daily trough monitoring for five to seven days. Critically, these two interactions are mechanistically independent and must both be managed simultaneously — the rifampin-voriconazole interaction does not mitigate the voriconazole-tacrolimus interaction, because rifampin acts on voriconazole's own metabolism while voriconazole's CYP3A4 inhibitory activity toward tacrolimus is unrelated to rifampin's induction effects.

Option A: Option A is incorrect; the directions are inverted — rifampin induces (does not inhibit) CYP enzymes, reducing voriconazole concentrations, and the interactions are not unpredictable or a reason to defer empiric dose adjustments.
Option B: Option B is incorrect; voriconazole does inhibit CYP3A4 but raises rifabutin concentrations, not rifampin concentrations — rifampin is not significantly a CYP substrate at clinical doses; and tacrolimus concentrations are markedly raised by voriconazole through CYP3A4 inhibition.
Option C: Option C is incorrect; rifampin's CYP induction is a systemic hepatic effect that dramatically reduces voriconazole concentrations regardless of the site of infection; the lung is not the primary site of voriconazole metabolism.
Option E: Option E is incorrect; the two interactions do not cancel each other — they affect different drugs through different mechanisms; rifampin's induction of CYP2C19 affects voriconazole's own clearance, while voriconazole's CYP3A4 inhibitory effect on tacrolimus operates independently and is not neutralized by rifampin's concurrent presence.

2. A patient with invasive aspergillosis receiving voriconazole 200 mg oral twice daily develops new visual hallucinations, photopsia, and mild confusion on Day 9 of therapy. A voriconazole trough drawn the previous morning is reported at 6.8 mg/L. The patient is a CYP2C19 poor metabolizer, a genotype not recognized at initiation. The patient remains hemodynamically stable and is responding to antifungal therapy by clinical and radiographic criteria. Which of the following represents the most appropriate next step?

A) Discontinue voriconazole immediately and switch to an echinocandin; concentration-dependent neurotoxicity at this level is irreversible and continuing the drug risks permanent harm
B) Reduce the voriconazole dose, targeting a trough within the 1.0 to 5.5 mg/L therapeutic window; repeat TDM after dose adjustment to confirm the trough has fallen into range; continue monitoring neuropsychiatric symptoms for resolution — voriconazole-associated neurotoxicity is concentration-dependent and typically reversible with dose reduction
C) Continue voriconazole at the current dose; a trough of 6.8 mg/L is acceptable in poor metabolizers because their therapeutic window is shifted upward relative to normal metabolizers
D) Add a CYP2C19 inhibitor such as omeprazole to deliberately raise voriconazole concentrations further, which paradoxically resolves neurotoxicity by saturating the toxic metabolite pathway
E) Switch to intravenous voriconazole at the same total daily dose; intravenous administration bypasses the hepatic metabolism responsible for neurotoxic metabolite accumulation in poor metabolizers

ANSWER: B

Rationale:

Option B is correct. Voriconazole-associated neurotoxicity — including visual hallucinations, photopsia, encephalopathy, and confusion — is a well-characterized concentration-dependent adverse effect that typically manifests when trough concentrations exceed 5.0 to 5.5 mg/L. At a trough of 6.8 mg/L, this patient is clearly in the supratherapeutic range, and the neuropsychiatric symptoms are consistent with voriconazole toxicity rather than an unrelated cause. Critically, voriconazole-associated neurotoxicity is reversible with dose reduction in the majority of cases — this distinguishes it from some other drug-induced neurological adverse effects and means that discontinuation of effective antifungal therapy is not required. The correct management is to reduce the voriconazole dose (for a CYP2C19 poor metabolizer, a substantial reduction — potentially halving the dose — is likely needed to achieve a trough in the 1.0 to 5.5 mg/L window), repeat TDM at the new steady state to confirm the trough has entered the therapeutic range, and monitor neuropsychiatric symptoms for resolution over days. Switching to an echinocandin sacrifices Aspergillus coverage unnecessarily when the more elegant solution — dose reduction — is available.

Option A: Option A is incorrect; voriconazole-associated neurotoxicity at supratherapeutic concentrations is concentration-dependent and reversible in most cases; discontinuing effective therapy when a dose reduction strategy is available is not the first-line management for stable, responding patients.
Option C: Option C is incorrect; there is no established separate therapeutic window for CYP2C19 poor metabolizers — the therapeutic window of 1.0 to 5.5 mg/L applies to all patients; poor metabolizer status explains why the trough is high, but does not expand the upper bound of acceptable concentrations.
Option D: Option D is incorrect; adding a CYP2C19 inhibitor to a patient already experiencing supratherapeutic toxicity would further raise voriconazole concentrations, worsening rather than resolving the clinical situation; this approach has no pharmacological basis for resolving neurotoxicity.
Option E: Option E is incorrect; intravenous voriconazole undergoes the same hepatic CYP2C19-mediated metabolism as oral voriconazole — the route of administration does not change the metabolic pathway, and switching to IV at the same dose would not reduce accumulation in a poor metabolizer.

3. A patient undergoing induction chemotherapy for acute myeloid leukemia is receiving posaconazole oral suspension 200 mg three times daily for antifungal prophylaxis. The patient develops grade 3 mucositis, is taking lansoprazole for gastrointestinal symptoms, and has reduced oral intake with predominantly liquid meals. A Day 7 trough returns at 0.38 mg/L — well below the prophylaxis target of 0.7 mg/L. The team asks which factors are contributing to the subtherapeutic level and what should be done. Which of the following correctly identifies all contributing pharmacokinetic factors and the most appropriate management?

A) Only the lansoprazole is responsible — proton pump inhibitors are the sole cause of posaconazole suspension failure; stopping lansoprazole will restore therapeutic concentrations without formulation change
B) Only the mucositis is responsible — mucosal damage prevents gastrointestinal absorption of all orally administered drugs equally; switching to any oral formulation will fail and intravenous therapy is the only option
C) Reduced oral intake alone explains the subtherapeutic trough — posaconazole suspension requires caloric intake to stimulate bile secretion; resuming a full diet will correct absorption without other changes
D) The subtherapeutic trough results solely from the three-times-daily dosing schedule — the suspension is approved only for twice-daily dosing and the frequency must be corrected before considering formulation changes
E) All three factors are contributing independently: lansoprazole (a proton pump inhibitor) raises gastric pH and impairs acid-dependent posaconazole dissolution; mucositis damages the gastrointestinal epithelium and reduces absorptive surface area; reduced oral and especially fatty food intake removes the bile-dependent micellar solubilization that posaconazole suspension requires for optimal absorption; each factor alone would reduce trough concentrations, and together they produce the profound subtherapeutic level observed; the most appropriate management is to switch to posaconazole delayed-release tablet or intravenous posaconazole, as the oral suspension cannot be reliably rescued in this clinical context

ANSWER: E

Rationale:

Option E is correct. Posaconazole oral suspension absorption depends on three pharmacokinetic conditions that are all simultaneously compromised in this patient. First, the suspension requires an acidic gastric environment for optimal solubilization and dissolution; lansoprazole (a proton pump inhibitor) elevates intragastric pH, impairing this step and reducing posaconazole absorption by 40 to 50% in clinical studies. Second, optimal absorption requires the presence of dietary fat, which stimulates bile secretion and promotes micellar incorporation of this highly lipophilic drug into lymphatic uptake pathways; the patient's reduced intake and liquid meals substantially deprive the drug of this absorption-enhancing mechanism. Third, mucositis damages the gastrointestinal mucosal epithelium — the site of absorption — reducing both absorptive surface area and transit-mediated uptake. The combination of all three factors operating simultaneously produces the profound subtherapeutic trough observed. The appropriate management is to change formulation rather than attempt to rescue the suspension in this context: posaconazole delayed-release tablet absorbs independently of gastric pH and does not require food fat content, making it substantially more reliable in this patient; intravenous posaconazole bypasses gastrointestinal absorption entirely and is the definitive solution when oral administration is unreliable.

Option A: Option A is incorrect; while lansoprazole does contribute significantly to the subtherapeutic trough, it is not the sole cause — mucositis and reduced fat intake are independently contributing factors, and stopping lansoprazole alone would be unlikely to bring the trough above 0.7 mg/L in the context of grade 3 mucositis and liquid diet.
Option B: Option B is incorrect; mucositis impairs mucosal absorption but does not equally affect all oral formulations — the posaconazole delayed-release tablet uses a polymer matrix delivering drug to a broader segment of intestine and is less mucositis-sensitive than the suspension; IV therapy is appropriate but not the only option.
Option C: Option C is incorrect; reduced oral intake explains part of the subtherapeutic trough, but dismissing the proton pump inhibitor and mucositis contributions is pharmacokinetically incomplete and would lead to inadequate management.
Option D: Option D is incorrect; posaconazole suspension is approved for three-times-daily dosing for prophylaxis in some guidelines, and the dose frequency is not the pharmacokinetic issue in this case — the absorption failure from three independent factors is.

4. A patient with HIV-associated invasive aspergillosis is receiving voriconazole and has a CYP2C19 poor metabolizer genotype. The patient's HIV regimen is being optimized and the team considers adding rifabutin for Mycobacterium avium complex prophylaxis. A pharmacist flags this combination as a bidirectional interaction. Which of the following correctly characterizes both directions of the voriconazole-rifabutin interaction and the clinical significance in this patient?

A) Voriconazole inhibits CYP3A4, raising rifabutin concentrations and increasing risk of rifabutin-associated toxicity including uveitis, leukopenia, and skin discoloration; simultaneously, rifabutin induces CYP2C19 and CYP3A4, lowering voriconazole concentrations — in this CYP2C19 poor metabolizer, who already has higher voriconazole levels than normal metabolizers, the rifabutin induction may paradoxically bring voriconazole into or below the therapeutic range, but the more immediate concern is rifabutin toxicity from CYP3A4 inhibition; the combination requires rifabutin dose reduction, voriconazole TDM, and close monitoring for rifabutin adverse effects
B) Rifabutin has no effect on voriconazole concentrations because CYP2C19 poor metabolizers rely entirely on CYP3A4 for voriconazole clearance, which rifabutin does not significantly inhibit; only the voriconazole-rifabutin direction is clinically relevant
C) Both drugs inhibit CYP3A4, producing additive immunosuppression that increases opportunistic infection risk; the primary management is to add a third antifungal agent to cover for this gap
D) The interaction is clinically insignificant in poor metabolizers because absent CYP2C19 activity means rifabutin induction of this isoform has no pharmacological substrate to act on; standard doses of both drugs can be used without modification
E) Voriconazole and rifabutin compete for the same hepatic uptake transporter; the clinical consequence is unpredictable hepatotoxicity that cannot be anticipated from enzyme-based interaction models

ANSWER: A

Rationale:

Option A is correct. The voriconazole-rifabutin interaction is genuinely bidirectional and involves two distinct mechanisms. In the first direction, voriconazole is a potent CYP3A4 inhibitor, and rifabutin is a CYP3A4 substrate; voriconazole significantly raises rifabutin plasma concentrations, increasing the risk of rifabutin concentration-dependent toxicity including anterior uveitis (the most characteristic and serious adverse effect), leukopenia, thrombocytopenia, and orange skin and body fluid discoloration. To use the combination at all, rifabutin dose reduction is required. In the second direction, rifabutin is a moderate CYP2C19 and CYP3A4 inducer — less potent than rifampin but clinically significant — and induces the enzymes responsible for voriconazole metabolism, lowering voriconazole concentrations. In a CYP2C19 poor metabolizer, this second direction deserves specific interpretation: because the patient lacks functional CYP2C19 to begin with, rifabutin's induction of the residual CYP3A4-mediated voriconazole clearance pathway may produce variable effects on voriconazole concentrations depending on the degree of CYP3A4 induction. Paradoxically, if the patient's voriconazole concentrations were supratherapeutic due to PM status, rifabutin induction might actually bring them closer to the therapeutic window — but this cannot be predicted reliably without TDM, and the primary immediate concern is rifabutin toxicity from elevated rifabutin concentrations. TDM of voriconazole and close clinical monitoring for rifabutin toxicity are mandatory.

Option B: Option B is incorrect; CYP2C19 poor metabolizers rely more heavily on CYP3A4 for residual voriconazole clearance precisely because CYP2C19 is non-functional, making them potentially more sensitive, not less, to CYP3A4 induction by rifabutin; the rifabutin-to-voriconazole direction is clinically relevant.
Option C: Option C is incorrect; the pharmacologically meaningful interaction is metabolic enzyme-based, not additive immunosuppression, and adding a third antifungal does not address the pharmacokinetic problem.
Option D: Option D is incorrect; rifabutin induces CYP3A4 as well as CYP2C19, and CYP3A4-mediated voriconazole clearance is the dominant remaining pathway in a CYP2C19 poor metabolizer; the interaction remains relevant and dose modification cannot be assumed safe without TDM.
Option E: Option E is incorrect; the primary voriconazole-rifabutin interaction mechanism is CYP enzyme-based, not hepatic uptake transporter competition; this distractor conflates the pharmacological basis of the interaction.

5. A renal transplant recipient maintained on sirolimus-based immunosuppression develops proven invasive pulmonary aspergillosis. Voriconazole is the treatment of choice. The transplant team debates the correct management sequence. One resident suggests starting voriconazole immediately and simultaneously reducing the sirolimus dose by 80% to account for the expected drug interaction. Another suggests transitioning off sirolimus before starting voriconazole. Which approach is correct, and why?

A) Starting voriconazole immediately with an 80% sirolimus dose reduction is the correct approach; the magnitude of the CYP3A4 interaction can be reliably managed with empiric dose reduction and TDM without the delay of an immunosuppressant transition
B) Both approaches are equally acceptable; the choice between them depends on center-specific transplant protocols rather than pharmacokinetic principles
C) Transitioning the patient off sirolimus before starting voriconazole is the pharmacologically correct approach because even an 80% sirolimus dose reduction will leave a starting dose that, when multiplied by the 10-fold or greater CYP3A4-inhibition-driven concentration increase from voriconazole, may still produce supratherapeutic and toxic sirolimus levels — and the interaction magnitude is too unpredictable to reliably dose-reduce to a safe target; the preferred strategy is to switch sirolimus to an alternative immunosuppressant (tacrolimus or cyclosporine, which have manageable and well-characterized azole interactions) before initiating voriconazole
D) Voriconazole is contraindicated in all sirolimus-treated patients regardless of any management strategy; an alternative antifungal must always be used
E) The correct approach is to continue sirolimus at the current dose and add voriconazole at half the standard dose; this preserves immunosuppression efficacy while reducing the CYP inhibitory impact of voriconazole on sirolimus metabolism

ANSWER: C

Rationale:

Option C is correct. The fundamental pharmacokinetic problem with sirolimus and potent CYP3A4-inhibiting azoles such as voriconazole or posaconazole is the extreme sensitivity of sirolimus to CYP3A4 inhibition. Unlike tacrolimus — where an approximately 3- to 5-fold AUC increase is expected and can be managed by reducing the dose to one-third — sirolimus concentrations may rise 10-fold or more when a potent azole is added, and the relationship between dose reduction and resulting concentration is far less predictable because of sirolimus's own non-linear and erratic pharmacokinetics, very long half-life of approximately 60 hours, and extensive tissue distribution. Even if the team attempts an aggressive 80% dose reduction, the starting concentration of sirolimus after dose reduction may still be driven to toxic levels by the CYP3A4 inhibition, and the long half-life means that toxicity can develop before TDM-guided adjustments take effect. The pharmacologically sound approach is to transition from sirolimus to an alternative immunosuppressant — tacrolimus is commonly used — whose interaction with voriconazole is well characterized, predictable, and safely manageable with the standard one-third dose reduction and daily trough monitoring protocol. This transition should occur before the first voriconazole dose so that the initial immunosuppressant-azole steady state is established under controlled conditions.

Option A: Option A is incorrect; an 80% sirolimus dose reduction does not reliably prevent toxicity because the interaction magnitude for sirolimus exceeds that for tacrolimus, the long half-life delays equilibration, and TDM-guided titration of sirolimus is considerably less standardized than tacrolimus TDM; the prescribing information for voriconazole lists concurrent sirolimus as contraindicated.
Option B: Option B is incorrect; this is not a matter of center preference — the pharmacokinetics of sirolimus and the magnitude of the interaction create an objective clinical hazard that standard empiric dose reduction cannot reliably manage; the approach is not equivalent to immunosuppressant transition.
Option D: Option D is incorrect; voriconazole is not absolutely contraindicated in all patients who have ever received sirolimus — the contraindication is concurrent use; transitioning off sirolimus resolves the contraindication and allows voriconazole to be used.
Option E: Option E is incorrect; halving the voriconazole dose does not meaningfully reduce voriconazole's CYP3A4 inhibitory activity toward sirolimus — CYP3A4 inhibition by voriconazole occurs at concentrations below its therapeutic trough, and reducing the voriconazole dose would risk subtherapeutic antifungal exposure while not eliminating the sirolimus interaction.

6. A patient with a mechanical mitral valve requiring therapeutic anticoagulation was maintained on warfarin with a stable INR of 2.6. Six weeks ago, fluconazole was started for esophageal candidiasis, the warfarin dose was reduced from 5 mg daily to 2.5 mg daily to compensate for the interaction, and the INR restabilized at 2.5. Fluconazole was discontinued one week ago. Today's INR is 1.4. The patient is asymptomatic. Which of the following is the correct mechanistic explanation and management plan?

A) The INR of 1.4 represents warfarin resistance that has developed during fluconazole therapy due to upregulation of vitamin K epoxide reductase; the reduced dose of warfarin is now permanently inadequate and the dose must be permanently increased
B) Fluconazole suppressed hepatic vitamin K synthesis during treatment; after fluconazole discontinuation, vitamin K synthesis has recovered, increasing clotting factor production and reducing the INR; vitamin K supplementation is required
C) The low INR reflects rebound hypercoagulability — a well-described phenomenon after azole discontinuation in anticoagulated patients — that requires immediate bridging anticoagulation with heparin
D) Fluconazole's CYP2C9 inhibition suppressed S-warfarin clearance during co-administration, allowing the reduced warfarin dose of 2.5 mg to maintain a therapeutic INR; after fluconazole discontinuation, CYP2C9 activity has recovered and S-warfarin is now cleared at its normal pre-fluconazole rate — the 2.5 mg dose that was calibrated against inhibited clearance is now insufficient, and the warfarin dose must be increased toward the pre-fluconazole baseline of 5 mg, with INR rechecked within one to two weeks; the patient's mechanical valve increases the urgency of maintaining therapeutic anticoagulation
E) The subtherapeutic INR is caused by fluconazole-induced CYP2C9 enzyme synthesis persisting after drug discontinuation; the liver continues to produce excess CYP2C9 for several months after the azole is stopped, accelerating warfarin clearance beyond the pre-treatment baseline

ANSWER: D

Rationale:

Option D is correct. This clinical scenario demonstrates the pharmacokinetic consequence of azole discontinuation on a co-administered CYP2C9 substrate — the reverse of the interaction that required dose reduction at initiation. During fluconazole therapy, CYP2C9 inhibition slowed S-warfarin metabolism, meaning that the reduced warfarin dose of 2.5 mg daily was sufficient to maintain a therapeutic INR of 2.5 because S-warfarin accumulated to concentrations adequate for anticoagulation despite the lower dose. After fluconazole discontinuation, the CYP2C9 inhibitory effect resolves within two to five days as fluconazole is cleared. S-warfarin clearance then normalizes to its pre-fluconazole rate, and the 2.5 mg dose — calibrated against the inhibited clearance state — produces insufficient S-warfarin exposure for therapeutic anticoagulation. The result is the predictable fall in INR to 1.4. Management requires increasing the warfarin dose back toward the pre-fluconazole baseline (5 mg daily as the starting point), with INR recheck within one to two weeks. The mechanical mitral valve adds clinical urgency: subtherapeutic anticoagulation in patients with mechanical valves carries significant risk of valve thrombosis and systemic embolism, making prompt INR correction critical.

Option A: Option A is incorrect; fluconazole does not induce warfarin resistance through vitamin K epoxide reductase upregulation — the reduced INR results from normalized warfarin clearance after CYP2C9 inhibition resolves, not from a permanent change in pharmacodynamic sensitivity.
Option B: Option B is incorrect; fluconazole does not suppress hepatic vitamin K synthesis — it acts as a CYP enzyme inhibitor affecting warfarin metabolism, not as a modifier of vitamin K production; this explanation conflates the mechanism of warfarin action with the mechanism of the drug interaction.
Option C: Option C is incorrect; rebound hypercoagulability after azole discontinuation is not an established pharmacological phenomenon — the subtherapeutic INR results from the straightforward pharmacokinetic consequence of normalized S-warfarin clearance, not from a rebound prothrombotic state; bridging heparin is not indicated for an INR of 1.4 as the primary management step when warfarin dose adjustment will resolve the issue.
Option E: Option E is incorrect; fluconazole is a CYP2C9 inhibitor, not an inducer — it does not stimulate CYP2C9 enzyme synthesis; after discontinuation, CYP2C9 activity returns to the pre-fluconazole baseline, not to a supranormal induced state.

7. A 58-year-old patient with onychomycosis is started on itraconazole pulse therapy. The patient's medication list includes simvastatin 40 mg daily for hyperlipidemia. A pharmacist identifies a clinically important drug interaction and recommends a statin switch. Which of the following correctly explains the interaction and identifies the safest statin alternatives?

A) Itraconazole inhibits CYP2D6, which metabolizes all statins equally; the entire statin class must be discontinued during itraconazole therapy and restarted only after the course is complete
B) Itraconazole is a potent CYP3A4 inhibitor; simvastatin and lovastatin are CYP3A4-dependent statins whose plasma concentrations rise markedly with CYP3A4 inhibition, dramatically increasing myopathy and rhabdomyolysis risk; pravastatin and rosuvastatin are not significantly CYP3A4-dependent and are the preferred alternatives — pravastatin is renally cleared and rosuvastatin undergoes minimal CYP metabolism — making either a safer choice during itraconazole co-administration
C) Itraconazole inhibits the hepatic uptake transporter OATP1B1, which affects all statins equally; any statin can be used safely with itraconazole if the dose is halved
D) The itraconazole-simvastatin interaction is clinically insignificant at standard pulse therapy doses because the short duration of itraconazole exposure prevents meaningful CYP enzyme inhibition from accumulating
E) Simvastatin can be continued safely during itraconazole therapy if the simvastatin dose is reduced by 50%; this dose reduction reliably prevents myopathy without requiring a statin switch

ANSWER: B

Rationale:

Option B is correct. Itraconazole is a potent inhibitor of CYP3A4, the primary metabolic pathway for simvastatin and lovastatin. When CYP3A4 is inhibited, simvastatin and lovastatin plasma concentrations rise substantially — in pharmacokinetic interaction studies, itraconazole has been shown to increase simvastatin area under the concentration-time curve by approximately 10- to 20-fold. At supratherapeutic statin concentrations, the risk of skeletal muscle toxicity increases markedly, ranging from myalgia to severe rhabdomyolysis with acute kidney injury. For this reason, simvastatin and lovastatin are contraindicated with potent CYP3A4 inhibitors including the azole antifungals. The appropriate management is to switch to a statin not dependent on CYP3A4 for its primary elimination. Pravastatin is cleared primarily by renal excretion and undergoes minimal hepatic CYP metabolism, making it unaffected by CYP3A4 inhibition. Rosuvastatin undergoes minimal CYP2C9-mediated metabolism with no significant CYP3A4 contribution, and is similarly safe with CYP3A4 inhibitors. Fluvastatin (CYP2C9) and pitavastatin are also acceptable alternatives. Atorvastatin is partially CYP3A4-dependent but has a wider safety margin than simvastatin; use with caution and dose reduction may be appropriate if switching to pravastatin or rosuvastatin is not feasible.

Option A: Option A is incorrect; itraconazole does not primarily inhibit CYP2D6 — it inhibits CYP3A4, and not all statins are equally CYP3A4-dependent; discontinuing the entire statin class is not necessary when safer alternatives exist.
Option C: Option C is incorrect; while itraconazole does inhibit OATP1B1 to a degree, the primary statin interaction is via CYP3A4 inhibition, not transporter inhibition alone; and the effect on statins is not equal across the class — simvastatin and lovastatin are disproportionately affected due to their near-complete CYP3A4 dependence.
Option D: Option D is incorrect; itraconazole pulse therapy produces plasma concentrations sufficient for significant CYP3A4 inhibition throughout each pulse period; the short duration does not prevent clinically important concentration increases in CYP3A4-dependent statins, and the risk of myopathy is real even with pulse therapy.
Option E: Option E is incorrect; a 50% dose reduction of simvastatin does not reliably prevent myopathy when CYP3A4 inhibition is expected to increase simvastatin concentrations by 10- to 20-fold; the prescribing information for simvastatin contraindicates concurrent use with potent CYP3A4 inhibitors regardless of dose adjustment.

8. A patient starting voriconazole for invasive aspergillosis is also taking omeprazole 40 mg daily for gastroesophageal reflux. A pharmacist identifies a bidirectional CYP2C19-mediated interaction between the two drugs. Which of the following correctly characterizes both directions of this interaction and the net clinical relevance?

A) Omeprazole is primarily metabolized by CYP2C19; voriconazole's potent CYP2C19 inhibition reduces omeprazole clearance and raises omeprazole plasma concentrations — an effect that is generally not clinically dangerous given omeprazole's wide therapeutic index, but confirms that voriconazole inhibits CYP2C19 substrates; conversely, omeprazole's own CYP2C19 inhibitory activity reduces voriconazole clearance and raises voriconazole concentrations — meaning that omeprazole co-administration can produce higher-than-expected voriconazole troughs, particularly in patients who are already normal or intermediate metabolizers, and TDM at Day 5 to 7 is important to detect any supratherapeutic accumulation
B) Omeprazole induces CYP2C19, lowering voriconazole concentrations and requiring voriconazole dose escalation; voriconazole has no effect on omeprazole concentrations
C) The interaction is unidirectional: voriconazole raises omeprazole concentrations only; omeprazole does not affect voriconazole pharmacokinetics because it is not a CYP inhibitor
D) Both drugs inhibit each other's absorption in the gastrointestinal tract; separating administration times by four hours eliminates the interaction entirely
E) Omeprazole raises gastric pH, which directly impairs voriconazole tablet dissolution; the pharmacokinetic interaction is an absorption interaction, not a metabolic one, and applies only to oral voriconazole formulations

ANSWER: A

Rationale:

Option A is correct. Both voriconazole and omeprazole are metabolized by CYP2C19, and both have inhibitory activity at this isoform, producing a bidirectional interaction. In the first direction, voriconazole is a potent CYP2C19 inhibitor; omeprazole is primarily cleared by CYP2C19-mediated hydroxylation and demethylation; voriconazole co-administration raises omeprazole plasma concentrations. Because omeprazole has a wide therapeutic index for its intended indication, this concentration increase is generally not clinically dangerous — elevated omeprazole concentrations cause more profound acid suppression but do not produce serious toxicity in most patients. However, this direction of the interaction confirms voriconazole's CYP2C19 inhibitory activity and has practical implications for other CYP2C19-dependent drugs with narrower therapeutic indices. In the second direction, omeprazole itself has moderate CYP2C19 inhibitory activity; when omeprazole is added to a patient receiving voriconazole, it reduces voriconazole's own CYP2C19-mediated clearance and raises voriconazole trough concentrations. The clinical significance of this direction depends on the patient's baseline CYP2C19 metabolizer status: in normal metabolizers, the omeprazole-driven increase in voriconazole concentrations may bring troughs into or above the therapeutic range depending on the starting level; in patients who are already at the upper end of the therapeutic window, omeprazole co-administration can precipitate supratherapeutic concentrations and toxicity. TDM at Day 5 to 7 is particularly important when omeprazole is part of the regimen.

Option B: Option B is incorrect; omeprazole is a CYP2C19 inhibitor, not an inducer — it raises rather than lowers voriconazole concentrations; voriconazole does affect omeprazole concentrations through CYP2C19 inhibition.
Option C: Option C is incorrect; the interaction is genuinely bidirectional — omeprazole's CYP2C19 inhibitory activity does affect voriconazole pharmacokinetics and raises voriconazole concentrations; characterizing it as unidirectional is pharmacologically incorrect.
Option D: Option D is incorrect; this is a metabolic, not an absorption, interaction — both drugs compete for the same metabolic enzyme in the liver; separating administration times does not eliminate enzyme-based metabolic interactions.
Option E: Option E is incorrect; while acid suppression by omeprazole does reduce posaconazole suspension absorption (as discussed in earlier modules in this series), voriconazole oral tablets do not have the same gastric pH-dependent dissolution mechanism; the voriconazole-omeprazole interaction is a metabolic CYP2C19 interaction, not an absorption interaction.

9. A patient with alcoholic cirrhosis (Child-Pugh class B) develops invasive aspergillosis in the setting of hepatic decompensation. The team plans to initiate intravenous voriconazole. A pharmacist notes that hepatic impairment significantly affects voriconazole pharmacokinetics and that standard dosing will require modification. Which of the following correctly describes the recommended voriconazole dose adjustment in Child-Pugh class B hepatic impairment and the pharmacokinetic rationale?

A) Both the loading dose and maintenance dose must be halved in Child-Pugh class B; reduced hepatic blood flow decreases voriconazole delivery to liver enzymes, reducing both initial distribution and ongoing clearance equally
B) No dose adjustment is required in Child-Pugh class B; voriconazole is primarily renally eliminated and hepatic impairment does not significantly affect its clearance
C) The maintenance dose must be increased in hepatic impairment because cirrhosis reduces plasma protein binding of voriconazole, increasing the volume of distribution and requiring higher doses to achieve therapeutic free drug concentrations
D) Voriconazole is contraindicated in all degrees of hepatic impairment because its metabolism produces hepatotoxic metabolites that accumulate specifically in cirrhotic liver tissue
E) The loading dose remains standard (6 mg/kg intravenously twice for two doses) to achieve rapid therapeutic concentrations regardless of hepatic function; the maintenance dose is halved (from 4 mg/kg to 2 mg/kg intravenously twice daily) because Child-Pugh B hepatic impairment reduces CYP2C19 and CYP3A4 activity, slowing voriconazole clearance and causing accumulation at standard maintenance doses; TDM at Day 4 to 5 is essential to guide further dose adjustments

ANSWER: E

Rationale:

Option E is correct. Voriconazole's pharmacokinetic behavior in hepatic impairment follows a principle applicable to many hepatically metabolized drugs: the loading dose, which is designed to rapidly fill the volume of distribution and achieve therapeutic concentrations, is determined by the volume of distribution rather than by hepatic clearance, and therefore does not require adjustment in hepatic impairment; it remains 6 mg/kg intravenously every 12 hours for two loading doses. The maintenance dose, by contrast, is designed to replace drug eliminated between doses — it is directly proportional to clearance, which is reduced in hepatic impairment. In Child-Pugh class B cirrhosis, CYP2C19 and CYP3A4 activity are reduced as functional hepatocellular mass decreases, slowing voriconazole clearance and causing accumulation at standard maintenance doses. The prescribing information recommends halving the maintenance dose to 2 mg/kg intravenously twice daily in Child-Pugh A and B impairment. Because hepatic impairment adds another layer of pharmacokinetic variability on top of CYP2C19 genotype-driven variability, TDM is critically important in these patients — both to confirm therapeutic concentrations are achieved and to detect supratherapeutic accumulation. Child-Pugh C (severe) hepatic impairment has limited pharmacokinetic data and voriconazole should be used with extreme caution.

Option A: Option A is incorrect; only the maintenance dose is adjusted, not the loading dose; reducing the loading dose would delay achievement of therapeutic concentrations and risk early treatment failure during aspergillosis.
Option B: Option B is incorrect; voriconazole is primarily hepatically metabolized, not renally eliminated — less than 2% is excreted unchanged in urine; hepatic impairment directly and significantly reduces its clearance.
Option C: Option C is incorrect; the dose adjustment in hepatic impairment is a reduction, not an increase; reduced clearance causes accumulation, not deficiency, at standard doses.
Option D: Option D is incorrect; voriconazole is not contraindicated in all degrees of hepatic impairment — it is used with dose adjustment and TDM guidance in Child-Pugh A and B; while hepatotoxicity is a recognized adverse effect at supratherapeutic concentrations, the solution is appropriate dosing and monitoring, not categorical contraindication.

10. A hematology-oncology patient with acute myeloid leukemia and invasive aspergillosis has a baseline QTc of 468 ms and is receiving multiple agents associated with QTc prolongation including ondansetron, haloperidol, and azithromycin. The infectious disease team selects isavuconazole rather than voriconazole for antifungal treatment. Beyond the lower calcineurin inhibitor interaction burden discussed elsewhere, what additional pharmacological property of isavuconazole makes it preferable in this specific patient?

A) Isavuconazole has no CYP3A4 inhibitory activity and therefore does not raise plasma concentrations of any co-administered QTc-prolonging drugs, directly reducing the cumulative QTc risk from pharmacokinetic interactions
B) Isavuconazole is the only triazole that does not require monitoring of QTc during therapy; voriconazole requires serial ECG monitoring by prescribing guidelines
C) Isavuconazole causes dose-dependent QTc shortening rather than prolongation; in a patient whose QTc is already elevated at 468 ms due to multiple QTc-prolonging agents, adding an antifungal that shortens the QTc — rather than one that prolongs it further — reduces the risk of accumulating additional QTc burden; this pharmacodynamic property directly favors isavuconazole over voriconazole in patients with baseline QTc prolongation or multiple QTc-prolonging co-medications
D) Isavuconazole undergoes renal elimination and does not interact with the hepatic pathways through which QTc-prolonging drugs exert their cardiac effects
E) Voriconazole causes severe QTc prolongation of more than 100 ms at therapeutic trough concentrations, making it absolutely contraindicated in any patient with a baseline QTc above 450 ms; isavuconazole is selected by default

ANSWER: C

Rationale:

Option C is correct. Isavuconazole has the pharmacodynamically distinctive property of causing dose-dependent QTc shortening — the QT interval decreases as isavuconazole plasma concentrations rise. This effect is opposite in direction to the QTc prolongation associated with most antifungals and many co-administered medications. In a patient with a baseline QTc of 468 ms already receiving three QTc-prolonging agents, the selection of an antifungal that shortens the QTc provides a pharmacodynamic advantage over one that prolongs it, because the risk of drug-induced torsades de pointes and ventricular arrhythmia increases with cumulative QTc burden. Voriconazole, at supratherapeutic concentrations, is associated with modest QTc prolongation, adding further to the patient's already elevated QTc. The QTc-shortening property of isavuconazole therefore makes it the pharmacologically rational choice in this specific clinical context, independent of its other advantages. It should be noted that QTc shortening itself is not entirely benign at extreme degrees — a markedly shortened QTc has been associated with arrhythmia risk in some contexts — but in a patient with an elevated baseline QTc due to other drugs, the net effect of isavuconazole is directionally favorable.

Option A: Option A is incorrect; isavuconazole does inhibit CYP3A4, albeit less potently than voriconazole — it does raise the concentrations of some CYP3A4-dependent co-administered drugs; the premise that it has no CYP3A4 inhibitory activity is inaccurate.
Option B: Option B is incorrect; there is no regulatory requirement for routine serial ECG monitoring with voriconazole that does not apply to isavuconazole; both agents require clinical monitoring for adverse effects, and the statement that only voriconazole requires QTc monitoring by prescribing guidelines is not accurate.
Option D: Option D is incorrect; isavuconazole undergoes primarily hepatic CYP3A4-mediated metabolism, not renal elimination — this is not the pharmacological basis for its cardiac safety advantage; the relevant property is the QTc-shortening pharmacodynamic effect.
Option E: Option E is incorrect; voriconazole does not cause severe QTc prolongation exceeding 100 ms at therapeutic concentrations and is not absolutely contraindicated above a QTc of 450 ms; the selection of isavuconazole is pharmacologically rational but not because voriconazole is categorically prohibited at this QTc.

11. A clinical pharmacist is asked by an ICU fellow why therapeutic drug monitoring is not performed for echinocandins (caspofungin, micafungin, anidulafungin) when it is mandatory for voriconazole. The pharmacist explains that TDM is only clinically valuable when specific pharmacokinetic and pharmacodynamic criteria are met. Which of the following correctly identifies the pharmacological reasons that TDM has not been established for echinocandins in routine clinical practice?

A) TDM is not performed for echinocandins because reliable assay methods for measuring echinocandin plasma concentrations have not yet been developed
B) Echinocandins are eliminated exclusively by the kidneys, and TDM is replaced by creatinine clearance-based dose adjustment formulas that predict concentrations without direct measurement
C) Echinocandin TDM is performed routinely in all transplant centers but is not yet standard practice in general ICU settings due to lack of awareness rather than lack of clinical rationale
D) Echinocandins lack the key criteria that make TDM clinically valuable: their pharmacokinetics are substantially more predictable than voriconazole across patients (lower interpatient variability), no validated therapeutic trough concentration range linked to efficacy or toxicity outcomes has been established for clinical use, and their therapeutic index for Candida infections is wide enough that standard weight-based or fixed dosing reliably achieves adequate antifungal exposure in most patients without the need for individual concentration monitoring
E) Echinocandin TDM is not performed because echinocandins are fungistatic rather than fungicidal, meaning plasma concentration targets are irrelevant to antifungal activity

ANSWER: D

Rationale:

Option D is correct. The decision to implement TDM for any drug requires that specific conditions be met: a defined therapeutic concentration window linked to both efficacy and toxicity, high interpatient pharmacokinetic variability making dose-to-concentration relationships unpredictable, and a narrow therapeutic index. Voriconazole satisfies all of these criteria forcefully — coefficient of variation for trough concentrations exceeds 80%, the therapeutic window of 1.0 to 5.5 mg/L is clearly defined, and standard dosing produces subtherapeutic concentrations in approximately 30 to 50% of patients and supratherapeutic concentrations in another 20 to 30%. Echinocandins, by contrast, have substantially more predictable pharmacokinetics: interpatient variability is lower, dose-to-concentration relationships are more consistent, and current evidence has not established a defined trough concentration range that reliably discriminates therapeutic success from failure or from toxicity in clinical settings. In the absence of a validated target range and evidence that TDM-guided dosing improves outcomes, routine echinocandin TDM is not part of standard clinical practice. This does not mean that pharmacokinetic data on echinocandins are unimportant — pharmacodynamic modeling suggests that area under the concentration-time curve to MIC (minimum inhibitory concentration) ratios drive echinocandin efficacy — but these parameters are not yet actionable in routine clinical TDM workflows.

Option A: Option A is incorrect; liquid chromatography-tandem mass spectrometry assays for echinocandin concentration measurement do exist and are used in research settings; the absence of routine TDM is not due to analytical unavailability.
Option B: Option B is incorrect; echinocandins are not renally eliminated — caspofungin and micafungin undergo hepatic metabolism and biliary excretion; anidulafungin undergoes chemical degradation; none of the three requires creatinine clearance-based dose adjustment in standard clinical use.
Option C: Option C is incorrect; echinocandin TDM is not routine at transplant centers — it is not performed as standard clinical practice at any center type; the premise that lack of awareness is the barrier misrepresents the evidence base.
Option E: Option E is incorrect; echinocandins are fungicidal against Candida species — this is a pharmacologically important property and one reason they are preferred for candidemia; the claim that they are fungistatic is factually incorrect.

12. A heart transplant recipient with a history of atrial fibrillation requiring therapeutic anticoagulation has been receiving tacrolimus, warfarin, and voriconazole concurrently for eight weeks for invasive aspergillosis. During treatment: tacrolimus was reduced to one-third of the pre-voriconazole dose and troughs are stable at 8 ng/mL; warfarin was reduced from 5 mg to 2 mg daily and the INR is stable at 2.6. Voriconazole therapy is now complete. Which of the following correctly identifies all simultaneous pharmacokinetic consequences of stopping voriconazole and the required monitoring for both co-administered drugs?

A) Stopping voriconazole removes CYP3A4 inhibition acting on tacrolimus — tacrolimus concentrations will fall as CYP3A4 activity recovers over two to five days, risking subtherapeutic immunosuppression and rejection; simultaneously, stopping voriconazole removes CYP2C9 inhibition acting on S-warfarin — S-warfarin clearance normalizes and the INR will fall from the loss of the inhibition-dependent anticoagulant effect; the tacrolimus dose must be increased toward the pre-voriconazole baseline with daily trough monitoring for five to seven days, and the warfarin dose must be increased toward its pre-voriconazole baseline with INR recheck within one to two weeks; both adjustments are required simultaneously and independently
B) Stopping voriconazole will cause both tacrolimus and warfarin concentrations to rise because the azole was competitively inhibiting their renal tubular secretion; dose reductions for both drugs are required after voriconazole is discontinued
C) Only tacrolimus requires adjustment after voriconazole discontinuation; warfarin is not significantly affected by azole discontinuation because the INR is maintained by dietary vitamin K intake rather than by drug concentration
D) Tacrolimus concentrations will rise after voriconazole is stopped because CYP3A4 enzyme synthesis is irreversibly suppressed by prolonged azole exposure; a further tacrolimus dose reduction is required
E) No dose adjustments are required for either drug after voriconazole is discontinued; the current reduced doses represent the new pharmacokinetic steady state for this patient and will remain appropriate after the azole is stopped

ANSWER: A

Rationale:

Option A is correct. This question integrates the full pharmacokinetic framework for azole discontinuation management across two simultaneously affected co-administered drugs. Stopping voriconazole removes two independent CYP inhibitory effects that were maintaining the current drug concentration steady states. The first effect: voriconazole inhibits CYP3A4, which metabolizes tacrolimus; this inhibition raised tacrolimus concentrations, requiring the one-third dose reduction that produced the current stable trough of 8 ng/mL. When voriconazole is stopped, CYP3A4 activity recovers over two to five days, tacrolimus metabolism accelerates to its pre-voriconazole rate, and concentrations fall — potentially to subtherapeutic levels with the current one-third dose. The tacrolimus dose must be proactively increased toward the pre-voriconazole dose (three times the current dose as a starting point) with daily trough monitoring for five to seven days to confirm re-establishment of the target trough range. The second effect: voriconazole inhibits CYP2C9, which metabolizes S-warfarin; this inhibition required the warfarin dose reduction from 5 mg to 2 mg to maintain a therapeutic INR of 2.6. When voriconazole is stopped, CYP2C9 activity normalizes, S-warfarin clearance increases, and the current 2 mg dose produces insufficient anticoagulant effect — the INR will fall. The warfarin dose must be increased toward the pre-voriconazole baseline of 5 mg with INR recheck within one to two weeks; the transplant status and atrial fibrillation add urgency. Both adjustments are required simultaneously, independently, and proactively — before concentrations drift to dangerous levels.

Option B: Option B is incorrect; the mechanisms are inverted — voriconazole inhibits hepatic CYP enzymes, not renal tubular secretion, and stopping it causes concentrations of CYP-dependent substrates to fall, not rise; dose increases, not reductions, are required after discontinuation.
Option C: Option C is incorrect; warfarin is significantly affected by azole discontinuation — the CYP2C9 interaction that required dose reduction at voriconazole initiation reverses at discontinuation, and the INR will fall to subtherapeutic levels if the warfarin dose is not adjusted; INR is not maintained by dietary vitamin K but by the balance of warfarin dose and warfarin clearance.
Option D: Option D is incorrect; CYP3A4 suppression from azole therapy is not irreversible — it is a pharmacokinetic interaction that resolves as the azole is cleared; after voriconazole discontinuation, CYP3A4 activity returns to normal, tacrolimus concentrations fall, and dose increase — not further reduction — is required.
Option E: Option E is incorrect; the reduced doses of both tacrolimus and warfarin were calibrated specifically against the CYP inhibitory effects of voriconazole; those effects reverse when voriconazole is stopped, and the reduced doses will produce subtherapeutic concentrations of both drugs; the current doses are not a new permanent steady state.

13. A resident presents a patient with candidemia and proposes fluconazole as empiric treatment, reasoning that fluconazole is first-line for Candida infections and has fewer drug interactions than echinocandins in this patient's medication list. Blood cultures subsequently speciate as Candida krusei. An infectious disease attending stops the fluconazole and explains that the choice was inappropriate for this species. Which of the following correctly explains the antifungal susceptibility profile that makes fluconazole inadequate for Candida krusei and identifies which other Candida species also presents susceptibility concerns with fluconazole?

A) Candida krusei is susceptible to fluconazole but requires higher doses than standard Candida albicans infections; increasing to 800 mg daily is sufficient to treat C. krusei candidemia
B) Candida krusei is intrinsically resistant to fluconazole — resistance is not acquired but is a species-defining characteristic present in all strains regardless of prior azole exposure; Candida glabrata (now reclassified as Nakaseomyces glabrata) presents a separate susceptibility concern as a species with dose-dependent susceptibility to fluconazole and a high capacity to acquire azole resistance through ERG11 mutations and efflux pump upregulation, making echinocandins the preferred empiric agent when either species is possible or confirmed
C) Fluconazole resistance in Candida krusei results from prolonged prior exposure to fluconazole in this patient and can be reversed by a drug holiday followed by reintroduction at higher doses
D) Candida krusei is resistant only to oral fluconazole due to poor gastrointestinal absorption of the drug when C. krusei is the infecting organism; intravenous fluconazole achieves adequate serum concentrations to treat C. krusei candidemia
E) All non-albicans Candida species are intrinsically resistant to fluconazole; the drug should never be used for any Candida infection except C. albicans

ANSWER: B

Rationale:

Option B is correct. Candida krusei intrinsic fluconazole resistance is a species-defining property that is not acquired through prior azole exposure — it is present in every C. krusei isolate tested, regardless of the patient's antifungal treatment history. The mechanism involves reduced affinity of C. krusei's ERG11-encoded lanosterol 14α-demethylase for fluconazole combined with constitutive overexpression of efflux pumps, making clinically achievable fluconazole concentrations insufficient to inhibit the organism. This is why empiric fluconazole for candidemia without speciation data carries risk in patients who might harbor C. krusei — and why echinocandins, which have activity against all Candida species including C. krusei, are preferred for empiric candidemia treatment in many guidelines. Candida glabrata (reclassified taxonomically as Nakaseomyces glabrata) presents a related but distinct concern: it is not intrinsically resistant to fluconazole but has dose-dependent susceptibility — some strains are susceptible at high fluconazole doses while others have acquired resistance — and it has a high capacity for azole resistance acquisition through ERG11 mutations and overexpression of CDR and MDR efflux pumps. Echinocandins are therefore preferred for both C. krusei and C. glabrata infections, with susceptibility testing guiding azole use where doses and testing support it.

Option A: Option A is incorrect; C. krusei intrinsic resistance is not a matter of insufficient fluconazole dosing — no clinically achievable or tolerated dose of fluconazole can overcome the resistance mechanism; increasing to 800 mg daily does not provide adequate activity against C. krusei.
Option C: Option C is incorrect; C. krusei fluconazole resistance is intrinsic and species-specific, not acquired from prior individual patient exposure — a drug holiday does not alter the resistance phenotype because the resistance is encoded in the organism's genome, not induced by treatment.
Option D: Option D is incorrect; C. krusei resistance is not limited to the oral formulation and is not a matter of bioavailability — intravenous fluconazole achieves high and reliable plasma concentrations in all patients but still does not achieve adequate activity against C. krusei because the organism's resistance mechanisms are not concentration-dependent at any clinically achievable level.
Option E: Option E is incorrect; not all non-albicans Candida species are intrinsically fluconazole-resistant — C. parapsilosis, C. tropicalis, and many other non-albicans species are fluconazole-susceptible; the blanket statement that all non-albicans species are resistant is factually incorrect and would inappropriately restrict fluconazole use.